Sankara Eye Foundation and Singapore-based Leben Care have developed a software-as-a-service retinal risk assessment platform in India called Netra.AI. It is a cloud-based artificial intelligence (AI) solution powered by Intel, which identifies the conditions of the retina in a short period of time using deep learning.
The AI solution is said to match the precision of human physicians. Netra.AI will also reduce the burden of detection for vitreoretinal surgeons, as it will be able to detect diabetic retinopathy (DR) in just a few minutes with the help of some images.
With Netra.AI, Sankara Eye Foundation and Leben Care have harnessed the power of Intel Xeon Scalable processors and built-in Intel Deep Learning (DL) Boost Technology to accurately detect DR and enable timely treatment to effectively combat visual impairment. and preventable blindness in diabetic patients, ”said Prakash Mallya, vice president and general manager of Intel India’s Sales, Marketing and Communications Group, in a statement.
How does this work
An image of the patient’s retina will be captured with the help of a fundus camera, which will be operated by technicians. The data collected from the image will be transferred securely and Netra.AI will perform an automatic analysis and compare the data from previous visits for the particular patient, if applicable.
The solution uses AI algorithms with a four-step deep convolutional neural network (DCNN). It can detect any damage based on pixel density in fundus images. After this, a report with bio identifiers is generated. The time it takes to produce detailed reports is just two minutes after photos are uploaded.
Netra.AI will also be able to diagnose retinal conditions such as glaucoma, macular degeneration and other retinal pathologies. The company says Netra.AI has screened 3,093 patients so far, of whom 742 were at risk (about 25 percent).
India will have 98 million cases of diabetic retinopathy by the year 2030, as it has one of the largest diabetic populations in the world. The speed and precision of the solution is expected to make it easier for doctors to assess and stop the damage, especially in areas where there is a shortage or absence of retinal specialists.